About eptacog beta
Recombinant activated factor VII
Used for
- Controls bleeding in adults and children with hemophilia A or B and inhibitors to clotting factors.
- Prevents bleeding during surgery or procedures in these patients.
Usual adult dose
Usually 75 micrograms/kg intravenously every 2–3 hours until bleeding is controlled; dosing varies by bleeding severity and clinical setting.
Usual dose in children
Usually 75 micrograms/kg intravenously every 2–3 hours; dosing varies by bleeding severity and clinical setting.
Common side effects
- Headache
- Dizziness
- Nausea
- Infusion-site reactions
Important warnings
- Can cause serious blood clots, including heart attack, stroke, or clots in other vessels.
- Use only under specialist supervision; monitor bleeding response and signs of clotting.
- Not for treating bleeding in people without hemophilia and inhibitors.
- Tell clinicians about other clotting medicines, including activated prothrombin complex concentrates.
Pregnancy
Limited human data; use only when clearly needed after weighing potential benefits and risks.
Breastfeeding
Unknown whether it passes into breast milk; use requires consideration of benefits and risks.
Interactions
- Activated prothrombin complex concentrates may increase clotting risk when used with eptacog beta.
- Other hemostatic agents may affect clotting risk; specialist monitoring is required.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.